Apyx Medical (APYX) Net Income towards Common Stockholders (2011 - 2026)

Apyx Medical has reported Net Income towards Common Stockholders for 16 years, with the latest figure at -$2.1 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 49.2% year-over-year to -$2.1 million; the trailing twelve-month figure through Mar 2026 stood at -$9.2 million (up 54.24% YoY), and the FY2025 full-year result was -$11.2 million, up 52.22% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$2.1 million, down from -$1.3 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$1.0 million in Q2 2023, with the low at -$9.6 million in Q4 2023.
• Historically, Net Income towards Common Stockholders has averaged -$4.6 million across 5 years, with a median of -$4.6 million in 2023.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders jumped 81.3% — and 2024, when it plunged 543.38%.
• Apyx Medical's Net Income towards Common Stockholders stood at -$6.1 million in 2022, then plunged by 58.4% to -$9.6 million in 2023, then surged by 51.83% to -$4.6 million in 2024, then jumped by 71.93% to -$1.3 million in 2025, then sank by 62.28% to -$2.1 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$2.1 million (Q1 2026), -$1.3 million (Q4 2025), and -$2.0 million (Q3 2025), per Business Quant data.